Elaine Finger's donation will go toward an endowed chair to advance education, research and innovation in business and health care at the University of Houston. Photo via uh.edu

A Houston philanthropist made a $2 million gift to the University of Houston to advance health care business innovation

Elaine Finger's donation will go toward an endowed chair to advance education, research and innovation in business and health care at the University of Houston. The Elaine W. Finger Endowed Chair in Health Care Business Innovation is a joint appointment in the C.T. Bauer College of Business and the Tilman J. Fertitta Family College of Medicine. The project will aim to catalyze innovative advancements to help the university into a leading hub for innovative solutions.

The endowment was made through the Bauer Foundation, and will be matched dollar-for-dollar via UH’s Aspire Fund. The Aspire Fund is a grant program created by the gift of an anonymous donor that matches all eligible gifts up to $50 million — for a total of $100 million — and is aimed to assist in education, health care innovation research, and industry outreach.

“An investment in health care business innovation is far more than a gift, it is a visionary commitment to the future of healthcare in Houston and beyond,” Diane Z. Chase, UH senior vice president for academic affairs and provost, says in a news release. “The establishment of this Chair is a testament to our shared dedication to developing solutions that will shape the health care landscape for generations to come.”

Bauer College launched the Healthcare Business Institute, or HBI, this summer to address research and innovative solutions for quality, cost and access concerns. HBI also works to connect students, faculty and researchers from Bauer, the Fertitta Family College of Medicine and the highly ranked health law program at the UH Law Center, and other UH programs.

UH will search for a new chair that according to the university, “will be considered a thought leader in health care innovation" and who is of high national prominence and able to elevate the stature of the University of Houston by bringing a record of achievements recognized by membership in the National Academy of Science, National Academy of Medicine or another national academy related to the field of study.

Ravi Aron, research director and professor of health care strategy, currently leads HBI.

UH's C. T. Bauer College of Business will house the newly launched Healthcare Business Institute. Photo via Getty Images

University of Houston introduces institute to bring business solutions to health care industry

medical biz

The University of Houston announced this month that it has now launched its new Healthcare Business Institute, which will work with medical and business leaders as well as students to find solutions to pressing issues in the health care industry, such as high costs, access to care and new innovative technologies.

The institute will be part of the university's C. T. Bauer College of Business and led by Ravi Aron, research director and professor of health care strategy and technology in the Bauer College Department of Decision & Information Sciences, and Dr. Edward Kroger, the administrative director of the center.

“Providers are facing increasingly limited reimbursement from the U.S. government, insurers and employers. The industry is, therefore, struggling with finding new ways to increase value by improving quality and decreasing cost,” Aron says in a statement. “This is complicated by the fact that the industry is the most heavily regulated in the country. While policy, regulations and the government all have roles to play, efficient care delivery also requires businesses–small, medium, large and startups-to play a significant role in delivering effective and efficient care.”

The institute plans to bring together stakeholders from device makers and pharmaceutical companies to angel investors and educators to address many of these issues. Faculty and partners will release impactful research on topics such as hospital operations, new health care technologies, AI and machine learning in hospital contexts, emerging financial models in health care and a number of other topics.

Research will be shared in a new practitioner-facing Knowledge Portal that will feature a journal, editorials, and other media components like blogs, videos and audio.

The HBI will also have an educational component, with formal degree-based and shorter non-degree tracts, as well as a masters program related to health care leadership. Multiple executive education programs are also in the works.

“This unique combination of researchers, educationists and students will also benefit by connecting to perhaps the world’s most diversified health care ecosystem,” Aron says in the statement.

And Houston is the right place to house such an institute, says Bauer College Dean and Cullen Distinguished Chair Professor Paul A. Pavlou.

“Technology, data, and AI are enabling unprecedented advances in medicine, and Houston’s impressive health care network presents an exciting opportunity for a Healthcare Business Institute,” Pavlou says in the release. “Not only is Houston home to the Texas Medical Center, UH is the only university in Houston that includes a large number of health care researchers at the Bauer College of Business, a world-ranked health law program at the UH Law Center, a computer science department with many distinguished research faculty, and a new College of Medicine."

“The opportunity for meaningful collaboration among health care researchers, industry leaders, and students through HBI will be a tremendous asset for Houston with the potential for local, national and global impact,” he continues.

Earlier this summer, UH announced plans to open a 70,000-square-foot innovation hub next to the M.D. Anderson Library on UH's main campus in 2025. It's slated to house a makerspace, the Cyvia and Melvyn Wolff Center for Entrepreneurship, the Energy Transition Institute, innovation programs, and Presidential Frontier Faculty labs and offices.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

7+ can't-miss Houston business and innovation events in June 2026

where to be

Editor's note: The FIFA World Cup comes to Houston this month, joined by major energy conferences and a lineup of fan-favorite, recurring events. Here’s what not to miss and how to register. Please note: this article may be updated to add more events.


June 1-4 — CLEANPOWER 2026 Conference and Exhibition

CLEANPOWER unites policymakers, experts, and corporate leaders to solve the challenges that none can solve alone. This must-attend, four-day conference is packed with cutting-edge discussions about wind, solar, storage, and transmission; dealmaking; networking; and fun.

This event begins June 1 at the George R. Brown Convention Center. Register here.

June 2 — Humans of Healthcare

Houston Methodist Center for Innovation will present its quarterly speaker series, Humans of Healthcare. The series will feature a panel of experts who will share about their career paths and discuss the nuances of the health care industry. This month's session will focus on today’s nursing landscape, the industry’s expectations of nurses and what career paths are possible in the field.

The event is Tuesday, June 2, from 5-6:30 p.m. at the Ion. Register here.

June 9 — Greentown Go Make Kickoff

Head to the Ion to celebrate the Greentown Go Make 2026 cohort. The open-innovation program with Shell Catalysts & Technologies and Technip Energies focuses on catalytic solutions for industrial decarbonization and the energy transition. Hear pitches from the founders and network with a select group of startups while enjoying food and drink.

This event is Tuesday, June 9, from 5:30-8 p.m. Register here.

June 9-10 — Texas Brain Economy Summit

The Center for Houston’s Future and UTMB are bringing the Texas Brain Economy Summit back to Houston this summer to continue to position the region as a global leader in brain health. Expect to hear from leaders of global institutions, including the World Economic Forum, U.S. Chamber of Commerce, McKinsey Health Institute, Global Brain Economy Initiative, Davos Alzheimer’s Collaborative, Business Collaborative for Brain Health (UsAgainstAlzheimer’s), Rice University, Memorial Hermann, MD Anderson and many others. Read InnovationMap's full preview of the event here.

This event begins Tuesday, June 9. Purchase tickets here.

June 10 — MIT Future of Healthcare Technology Forum

The MIT Club of South Texas will host an in-person forum to explore how innovation, government and policy are changing the healthcare industry. The event will feature MIT alumni and Houston healthcare leaders, including Dr. Tim Boone, dean of the Texas A&M School of Engineering Medicine; Cynthia Reinhart-King, chair of bioengineering at Rice University; Dr. Tony Lin, CEO and chairman emeritus of Kelsey-Seybold Clinic; and others.

This event is Wednesday, June 10, from 5:15-8:30 p.m. at the TAMU EnMed Building. Register here.

June 11 — Goals & Gigawatts: Houston Energy & Climate Week The Power of & Kickoff Party

Come watch the Mexico City FIFA opening match while celebrating energy and innovation at the Goals & Gigawatts Kickoff Party. The event will feature food, drinks, and a showcase on Houston Energy & Climate Week. Learn what to expect and how to get involved in HECW before closing the night with a DJ and karaoke.

This event is Thursday, June 11, from 1:30-6:30 p.m. Find more information here.

June 16-17 — Energy Projects Conference & Expo

The Energy Projects Conference & Expo (EPC Show) is the largest event in North America for professionals working at the heart of major energy projects. The essential event for engineering, construction, commissioning, operations and maintenance across multiple energy sectors brings together five leading conferences under one roof. Conference subjects span LNG exporting, hydrogen and ammonia, midstream, petrochem and refining, and sustainable aviation fuels.

This event begins June 16 at George R. Brown Convention Center. Register here.

June 25 – NASA Tech Talk

Every fourth Thursday of the month, NASA experts, including longtime engineer Montgomery Goforth, present on technology development challenges NASA’s Johnson Space Center and the larger aerospace community are facing, and how they can be leveraged by Houston’s innovation community. Stick around after for drinks and networking at Second Draught.

This event is Thursday, June 25, from 6-7 p.m. at the Ion. Register here.

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”